KINASE INHIBITORS
News & Literature Highlights
March 2021
February 2021
January 2021
December 2020
November 2020
-
Kinase Inhibitors
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
American Journal of Managed Care
October 2020
-
Kinase Inhibitors
Cardiovascular Toxicities of Bruton’s Tyrosine Kinase Inhibitors
Current Treatment Options in Oncology
September 2020
-
Kinase Inhibitors
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase II PACE Trial (NCT01207440) in Patients (pts) With Ph+ Leukemia
2020 ASCO Annual Meeting (Abstract/Poster)
-
Kinase Inhibitors
A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
Frontiers in Pharmacology
-
General Cardio-Oncology
The Role of Biomarkers to Evaluate Cardiotoxicity
Current Treatment Options in Oncology
-
General Cardio-Oncology
Preventing Today’s Survivors of Breast Cancer From Becoming Tomorrow’s Cardiac Patients
JCO Oncology Practice
-
General Cardio-Oncology
Innovation in Precision Cardio-Oncology During the Coronavirus Pandemic and Into a Post-pandemic World
Frontiers in Cardiovascular Medicine
August 2020
-
Kinase Inhibitors
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience
Oncology
-
Kinase Inhibitors
Precision Cardio-Oncology: A Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
Journal of Cardiovascular Translational Research
July 2020
-
Kinase Inhibitors
Electrocardiographic Changes Associated With Ibrutinib Exposure
Cancer Control
-
Kinase Inhibitors
Cardiotoxicity of the BCR-ABL1 Tyrosine Kinase Inhibitors: Emphasis on Ponatinib
International Journal of Cardiology
June 2020
May 2020
-
Kinase Inhibitors
Early Diagnosis, Clinical Management, and Follow-up of Cardiovascular Events with Ponatinib
Heart Failure Reviews
-
General Cardio-Oncology
Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation
The ASCO Post
-
General Cardio-Oncology
Metabolic Changes May Signal Development of Chemotherapy-Associated Cardiotoxicity
The ASCO Post
